A2AR的负基调节剂:癌症免疫治疗的新武器?
1Department of Chemical and Geological Sciences, University of Modena and Reggio Emilia, Modena I-41125, Italy.
Journal of medicinal chemistry
|January 30, 2025
概括
用新型负调节器准腺A2A受体 (A2A R) 为癌症免疫疗法提供了一个有前途的策略,通过克服瘤微环境中当前治疗方法的局限性,克服了癌症免疫疗法的局限性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 通过A2A受体 (A2A R) 传递腺素信号,促进瘤微环境 (TME) 的免疫抑制,阻碍抗癌免疫反应.
- 目前的A2A R抗剂面临挑战,包括竞争性结合和非目标效应,限制它们的治疗疗效.
研究的目的:
- 开发A2A R的新型负基调制剂 (NAM) 作为潜在的癌症免疫治疗策略.
- 评估这些A2A R NAM在高腺 TMEs中的疗效.
主要方法:
- 开发一系列新的A2A R NAMs.
- 在模拟高腺TME的临床前模型中评估NAM活性.
主要成果:
- 这种新型的A2A R NAMs在高氨酸TMEs中表现出强烈的活性.
- NAMs表现出一种非竞争性,和性机制,与orthosteric对抗剂相比,增强了受体选择性.
结论:
- A2A R NAMs代表了癌症免疫疗法的一种有前途的治疗方法.
- 这些发现突显了A2A R NAM在瘤学中的转化潜力,以增强抗癌免疫力.
更多相关视频
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
3.5K
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.6K
相关概念视频
Tumor Immunotherapy
466
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
466
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
531
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
531
Drug-Receptor Interaction: Agonist
2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K
